DDInter1825 DDInter131
Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
Tofacitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Tofacitinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esomeprazole
Tofacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Tofacitinib {u} may lead to a major life threatening interaction when taken with {v} Brexucabtagene autoleucel
Tofacitinib {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Modafinil
Tofacitinib may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Tofacitinib may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel
Tofacitinib may lead to a major life threatening interaction when taken with Fingolimod